Expertise in
2
conditions

Dr. Brian D. Weiss

Intensive Care Medicine
Select Specialty Hosp-Columbus
410 W 10th Ave, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
2
conditions
Select Specialty Hosp-Columbus
410 W 10th Ave, 
Columbus, OH 

Overview

Brian Weiss is an Intensive Care Medicine provider practicing medicine in Columbus, Ohio.

Dr. Weiss is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Legius Syndrome, Vascular Birthmark, Lithotripsy, and Fasciotomy.

He is actively involved in clinical research, co-authoring 71 peer reviewed articles and participating in 21 clinical trials.

Specialties

Intensive Care Medicine

Licenses

Emergency Medicine in OH

Hospital Affiliations

Thomas Jefferson University Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID

Locations

Select Specialty Hosp-Columbus
410 W 10th Ave, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors
Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors
Enrollment Status: Recruiting
Publish Date: August 24, 2026
Intervention Type: Combination product
Study Drug: Selumetinib
Study Phase: Phase 2
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Dinutuximab, Isotretinoin, Lenalidomide
Study Phase: Phase 1
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib
Study Phase: Phase 4
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Study Phase: Phase 1
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Enrollment Status: Active_not_recruiting
Publish Date: June 23, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

71 Total Publications

Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma.
Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma.
Journal: Science advances
Published: July 17, 2026
Similar Doctors
Expertise in
8
conditions
Dr. Richard J. Ko
Intensive Care Medicine | Sleep Medicine | Pulmonary Medicine
Expertise in
8
conditions
Dr. Richard J. Ko
Intensive Care Medicine | Sleep Medicine | Pulmonary Medicine
Referral may be required
Before you request

Ohiohealth Corporation

393 E Town St, 
Columbus, OH 
 (2.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Ko is an Intensive Care Medicine specialist and a Sleep Medicine provider practicing medicine in Columbus, Ohio. Dr. Ko is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Obstructive Sleep Apnea, Drowsiness, Excessive Daytime Sleepiness, and Insomnia. Dr. Ko is board certified in American Board Of Internal Medicine. Dr. Ko is currently accepting new patients.

Expertise in
3
conditions
Dr. Philip T. Diaz
Intensive Care Medicine
Expertise in
3
conditions
Dr. Philip T. Diaz
Intensive Care Medicine
Referral may be required
Before you request

Ohio State Martha Morehouse Outpatient Care

2050 Kenny Rd, 
Columbus,, OH 
 (0.9 miles away)
614-293-3890
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Philip Diaz is an Intensive Care Medicine provider practicing medicine in Columbus,, Ohio. Dr. Diaz is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Emphysema, Pulmonary Fibrosis, Lung Nodules, and Systemic Sclerosis (SSc). Dr. Diaz is currently accepting new patients.

Expertise in
7
conditions
Dr. Archana P. Hinduja
Intensive Care Medicine | Psychiatry | Neurology
Expertise in
7
conditions
Dr. Archana P. Hinduja
Intensive Care Medicine | Psychiatry | Neurology
Referral may be required
Before you request

Adena Medical Group LLC

272 Hospital Rd, 
Chillicothe, OH 
 (41.4 miles away)
740-779-8575
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Archana Hinduja is an Intensive Care Medicine specialist and a Psychiatrist practicing medicine in Chillicothe, Ohio. Dr. Hinduja is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Stroke, Apoplexy, Subarachnoid Hemorrhage, Thrombectomy, and Gastrostomy. Dr. Hinduja is board certified in American Board Of Psychiatry & Neurology. Dr. Hinduja is currently accepting new patients.

Frequently Asked Questions about Dr. Brian D. Weiss

How do I make an appointment with Dr. Brian D. Weiss?

You can book an appointment with Dr. Brian D. Weiss by calling their office at 614-293-2101. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brian D. Weiss a top-rated expert for Neurofibromatosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brian D. Weiss is classified as an Elite expert for Neurofibromatosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brian D. Weiss specialize in?

While Dr. Brian D. Weiss is a Intensive Care Medicine, they have specific expertise in Neurofibromatosis, Lithotripsy, and Legius Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Intensive Care Medicine.

Does Dr. Brian D. Weiss participate in research or clinical trials?

Yes. Dr. Brian D. Weiss has published 71 articles and abstracts on conditions like Neurofibromatosis. You can view a list of Dr. Brian D. Weiss's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brian D. Weiss accept my insurance?

Dr. Brian D. Weiss accepts most major insurance plans, including CareSource and Independent Health. We recommend calling the office directly at 614-293-2101 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weiss's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile